Published: Aug. 6, 2024
The combination of several therapeutic strategies is often seen as a good way to decrease the resistance rates, since bacteria overcome better single-drug treatments than multi-drug ones. This strategy especially attractive when targets and subpopulations are affected, it case Klebsiella pneumoniae persister cells, subpopulation able transiently survive antibiotic exposures. work aims evaluate potential repurposed anticancer drug, mitomycin C, combined with K. lytic phage vB_KpnM-VAC13 in vitro safety an vivo murine model against two clinical isolates this pathogen, one them exhibiting imipenem-persister phenotype. At same time, we verified absence toxicity C at concentration using human chondrocyte cell line T/C28a2. viability these cells was checked both by cytotoxicity assays flow cytometry.
Language: Английский